A Phase 3 interventional study of VIT-45 and Placebo in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.
Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 8th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 12th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:
Biocruces Bizkaia Health Research Institute · Sites in Spain
Ages 18+
Children's Hospital of Orange County
Ages 1–18
Helsinki University Central Hospital
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 24 · Phase 4 23
First in 2005; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 594 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 156 across the 54 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
19 studies in Anemia by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 19 studies in Anemia by Daiichi Sankyo, this one is the 4th largest by enrollment, is one of 6 that started in 2005, is one of 15 in phase 3, and was the 18th registered.
Daiichi Sankyo’s Anemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing ferric carboxymaltose in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 19 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia
Evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Day 0: 15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously. Day 7: for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously.
Drug: VIT-45 · Drug: Placebo
Day 0: for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously. Day 7: 15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously.
Drug: VIT-45 · Drug: Placebo
15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously
Also known as: ferric carboxymaltose
for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously
Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period
Number of participants with any treatment-emergent adverse events experienced by participants. The 7-day study period for Study Period 1 ended with the initiation of dosing for Study Period 2. The 7-day study period fo Study Period 2 ended with the completion of Day 14 procedures.
Time frame: Day 0 to 7
Hospitals and medical clinics
| Milestone | VIT-45/Placebo | Placebo/VIT-045 |
|---|---|---|
| Started | 305 | 289 |
| Completed | 291 | 277 |
| Not completed | 14 | 12 |
| Withdrew: Received blood transfusion | 0 | 1 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Selection criteria/study compliance | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Withdrawn by site due to non-compliance | 1 | 0 |
| Withdrew: Discontinued due to hurricane related issue | 1 | 1 |
| Withdrew: Unable to perform venipuncture for day 7, day 14 labs, and day 7 infusion | 1 | 0 |
| Withdrew: Unable to comply with study visits | 2 | 0 |
| Withdrew: Unable to access vein | 0 | 2 |
| Withdrew: Early term - patient could not return for second infusion due to thanksgiving holiday | 0 | 1 |
Number of participants with any treatment-emergent adverse events experienced by participants. The 7-day study period for Study Period 1 ended with the initiation of dosing for Study Period 2. The 7-day study period fo Study Period 2 ended with the completion of Day 14 procedures.
| participants | ViT-45 | Placebo |
|---|---|---|
| Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period | 174 | 114 |
Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VIT-45 on Day 0 or Day 7 | 1/584 (0.2%) | 2/584 (0.3%) | 31/584 (5.3%) |
| Placebo on Day 0 or Day 7 | 0/569 (0%) | 4/569 (0.7%) | 19/569 (3.3%) |
| Event | VIT-45 on Day 0 or Day 7 | Placebo on Day 0 or Day 7 |
|---|---|---|
| Diabetes mellitus non-insulin dependentMetabolism and nutrition disorders | 0/584 | 1/569 |
| HypertensionVascular disorders | 0/584 | 1/569 |
| Upper gastrointestinal hemorrhageGastrointestinal disorders | 0/584 | 1/569 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/584 | 1/569 |
| EndometritisInfections and infestations | 0/584 | 1/569 |
| FallInjury, poisoning and procedural complications | 0/584 | 1/569 |
| PneumoniaInfections and infestations | 1/584 | 0/569 |
| Intestinal obstructionGastrointestinal disorders | 1/584 | 0/569 |
| Event | VIT-45 on Day 0 or Day 7 | Placebo on Day 0 or Day 7 |
|---|---|---|
| HeadacheNervous system disorders | 31/584 | 19/569 |
Safety population: All subjects who received at least 1 dose of randomized study drug
| Age, Continuous(years) | VIT-45 | Placebo | Total |
|---|---|---|---|
| Mean | 41.2 ± 16.4325 | 42.6 ± 16.9296 | 41.9 ± 16.6767 |
| Sex: Female, Male(Participants) | VIT-45 | Placebo | Total |
|---|---|---|---|
| Female | 36 | 34 | 70 |
| Male | 269 | 255 | 524 |
| Race (NIH/OMB)(Participants) | VIT-45 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 49 | 52 | 101 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 190 | 178 | 368 |
| White | 62 | 48 | 110 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 11 | 15 |
| Region of Enrollment(participants) | VIT-45 | Placebo | Total |
|---|---|---|---|
| United States | 305 | 289 | 594 |
| Weight(kilograms) | VIT-45 | Placebo | Total |
|---|---|---|---|
| Mean | 80.6 ± 80.6 | 80.6 ± 80.6 | 80.6 ± 8.6 |
Plan to share: No
Ran from Jul 2005 to primary completion in Feb 2006, 7 months.
Results were first posted in Apr 2025, 19 years 2 months after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 7 months is below that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose